钠-葡萄糖协同转运蛋白抑制剂与心力衰竭的研究进展  

Evolving Future of Sodium Glucose Cotransporter-2 Inhibitor and Heart Failure

作　　者：高斯德 李卫萍[1] 李虹伟[1,2] GAO Side 1 ,LI Weiping 1 ,LI Hongwei 1,2(1.Department of Cardiology,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China; 2.Beijing Key Laboratory of Metabolic Disorder Related Cardiovascular Disease,Beijing 100069,Chin)

机构地区：[1]首都医科大学附属北京友谊医院心脏中心,北京100050 [2]代谢紊乱相关心血管疾病北京市重点实验室,北京100069

出　　处：《心血管病学进展》2018年第5期703-708,共6页Advances in Cardiovascular Diseases

基　　金：国家自然科学基金资助项目(81670315);北京自然科学基金资助项目(7172059)

摘　　要：糖尿病是血管病变、心室重构及心功能恶化的重要危险因素。在强调心血管获益的糖尿病治疗时代,钠-葡萄糖协同转运蛋白-2抑制剂(SGLT-2i)的发现无疑具有里程碑式的意义。越来越多的证据表明SGLT-2i具有多重的心血管保护作用,SGLT-2i治疗相比于安慰剂可显著改善糖尿病患者的心血管预后。令人欣慰的是,SGLT-2i能有效减少患者因心力衰竭发作再住院的风险,这一发现或将开启糖尿病合并心力衰竭治疗的新篇章,后续研究旨在探索SGLT-2i改善心肌病变的机制,并进一步明确SGLT-2i能否为已合并心力衰竭的患者带来获益。Diabetes is one of important risk factors for diabetic vascular complication,ventricular remodeling and deteriorated heart failure.The discovery of sodium glucose cotransporter-2 inhibitor（SGLT-2i）undoubtedly marks a milestone in the current diabetes treatment strategy for diabetes and emphasizes cardiovascular benefits while lowering glucose.An increasing amount of evidence suggests that SGLT-2i have multiple cardiovascular protective effects,which correlates with the latest findings that primary cardiovascular outcomes were markedly improved in diabetic patients treated with SGLT-2i as compared with placebo.Surprisingly,researchers also found that treatment with SGLT-2i was associated with a lower risk of hospitalization for heart failure,making SGLT-2i a promising novel therapeutic target for heart failure in diabetes.Subsequent studies will explore mechanisms responsible for cardiomyopathy and further testify whether SGLT-2i could bring benefits for heart failure patients.

关 键 词：钠-葡萄糖协同转运蛋白-2抑制剂 心血管获益 心力衰竭 

分 类 号：R541.6[医药卫生—心血管疾病]